Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Jyoti Nangalia, MBBChir FRCPath, Charles Massie, PhD, E Joanna Baxter, PhD, Francesca L Nice, MRes, Gunes Gundem, PhD, David Wedge, PhD, Edward Avezov, PhD, Juan Li, PhD, Karoline Kollmann, PhD, David G. Kent, PhD, Athar Aziz, PhD, Anna L Godfrey, BMBCh FRCPath, Jonathan Hinton, MSc, Inigo Martincorena, PhD, Peter Van Loo, PhD, Amy V Jones, PhD, Paola Guglielmelli, PhD MD, Patrick Tarpey, PhD, Heather P Harding, PhD, John D Fitzpatrick, BA, Calum T Goudie, BA, Christina A Ortmann, MD, Stephen J Loughran, PhD, Keiran Raine, MSc, David Jones, MSc, Adam Butler, MSc, Jon W Teague, MSc, Sarah O'Meara, Stuart McLaren, Michele Bianchi, Yvonne Silber, MSc, Danai Dimitropolou, BSc, David Bloxham, MSc FRCPath, Laura J Mudie, BSc, Mark Maddison, BSc, Ben Robinson, BSc, Clodagh Keohane, MD, Cathy MacLean, MSc, Kate Hill, BM BS, Kim H. Orchard, MBBS, PhD, FRCP, FRCPath, Sudhir Tauro, PhD, Ming-Qing Du, MB, PhD, Mel Greaves, PhD, FRS, David Bowen, MD, PhD, Brian Huntly, MBChB FRCPath PhD, Claire N Harrison, DM, FRCP, FRCPath, Nicholas C.P. Cross, PhD, FRCPath, David Ron, MD, Alessandro M Vannucchi, MD, Elli Papaemmanuil, PhD, Peter J. Campbell, PhD, Anthony R Green, FRCPath FMedSci

Blood (2013) 122 (21): LBA-2.

https://doi.org/10.1182/blood.V122.21.LBA-2.LBA-2

Published: 2013

Journal Articles

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Joannah Score, Claire Hidalgo-Curtis, Amy V. Jones, Nils Winkelmann, Alison Skinner, Daniel Ward, Katerina Zoi, Thomas Ernst, Frank Stegelmann, Konstanze Döhner, Andrew Chase, Nicholas C. P. Cross

Blood (2012) 119 (5): 1208–1213.

https://doi.org/10.1182/blood-2011-07-367243

Published: 2012

Includes: Supplemental data

Journal Articles

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

Paola Guglielmelli, MD, PhD, Flavia Biamonte, BiSc, Johannah Score, Claire Hidalgo-Curtis, PhD, Francisco Cervantes, MD, PhD, Margherita Maffioli, MD, Tiziana Fanelli, BiSci, Thomas Ernst, MD, Nils Winkelman, MD, Amy V Jones, PhD, Katerina Zoi, MD, PhD, Andreas Reiter, MD, Andrew Duncombe, MD, Laura Villani, Biol Sci, Chiara Paoli, BiSci, Alberto Bosi, MD, Giovanni Barosi, MD, Nicholas C.P. Cross, PhD, Alessandro M. Vannucchi, MD

Blood (2011) 118 (21): 2811.

https://doi.org/10.1182/blood.V118.21.2811.2811

Published: 2011

Journal Articles

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

Nicholas C.P. Cross, PhD, FRCPath, Joannah Score, PhD, Claire Hidalgo-Curtis, PhD, Amy V Jones, PhD, Nils Winkelmann, MD, Alison Skinner, BSc, Daniel Ward, MSc, Katerina Zoi, MD, PhD, Thomas Ernst, MD, Frank Stegelmann, MD, Konstanze Dohner, MD, PhD, Andrew J Chase, PhD

Blood (2011) 118 (21): 617.

https://doi.org/10.1182/blood.V118.21.617.617

Published: 2011

Journal Articles

EZH2 mutational status predicts poor survival in myelofibrosis

Paola Guglielmelli, Flavia Biamonte, Joannah Score, Claire Hidalgo-Curtis, Francisco Cervantes, Margherita Maffioli, Tiziana Fanelli, Thomas Ernst, Nils Winkelman, Amy V. Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Laura Villani, Alberto Bosi, Giovanni Barosi, Nicholas C. P. Cross, Alessandro M. Vannucchi

Blood (2011) 118 (19): 5227–5234.

https://doi.org/10.1182/blood-2011-06-363424

Published: 2011

Includes: Supplemental data

Journal Articles

Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms

Thomas Ernst, MD, Joannah Score, PhD, Claire E Hidalgo-Curtis, PhD, Amy V Jones, PhD, Andreas Hochhaus, MD, Dolors Colomer, MD, Francisco Cervantes, MD, Andrew J Chase, PhD, Nicholas C.P. Cross, PhD, FRCPath

Blood (2010) 116 (21): 625.

https://doi.org/10.1182/blood.V116.21.625.625

Published: 2010

Journal Articles

The JAK2 46/1 haplotype predisposes to MPL -mutated myeloproliferative neoplasms

Amy V. Jones, Peter J. Campbell, Philip A. Beer, Susanne Schnittger, Alessandro M. Vannucchi, Katerina Zoi, Melanie J. Percy, Mary Frances McMullin, Linda M. Scott, William Tapper, Richard T. Silver, David Oscier, Claire N. Harrison, Harald Grallert, Aliaksei Kisialiou, Paul Strike, Andrew J. Chase, Anthony R. Green, Nicholas C. P. Cross

Blood (2010) 115 (22): 4517–4523.

https://doi.org/10.1182/blood-2009-08-236448

Published: 2010

Includes: Supplemental data

Journal Articles

Decrease in JAK2 V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV).

Richard T. Silver, MD, Katherine Vandris, Joshua J. Goldman, Fernando Adriano, Y. Lynn Wang, MD, PhD, Amy V. Jones, Paul J. Christos, PhD, N. C.P. Cross, PhD

Blood (2009) 114 (22): 1908.

https://doi.org/10.1182/blood.V114.22.1908.1908

Published: 2009

Journal Articles

No Evidence for Increased Prevalence of JAK2 V617F in Women with a History of Recurrent Miscarriage

Issa J. Dahabreh, Amy V. Jones, Michael Voulgarelis, Christina Alafakis-Tzannatos, Stavroula Giannouli, Marighoula Varla-Leftherioti, Theodora Keramitsoglou, Christine Zoi, Dimitris Loukopoulos, Stelios Fotiou, Nicholas C.P. Cross, PhD, Katerina Zoi, PhD

Blood (2008) 112 (11): 5235.

https://doi.org/10.1182/blood.V112.11.5235.5235

Published: 2008

Journal Articles

Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype

Nicholas C.P. Cross, PhD, Amy V. Jones, BSc, Richard T. Silver, MD, David Oscier, MD, Georgia Metzgeroth, MD, Y. Lynn Wang, MD, PhD, Andrew Collins, PhD, Andreas Reiter, MD, Francis Grand, PhD, Andrew Chase, PhD

Blood (2008) 112 (11): 173.

https://doi.org/10.1182/blood.V112.11.173.173

Published: 2008

Journal Articles

JAK2 V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity.

Richard T. Silver, MD, Katherine Vandris, Y. Lynn Wang, M.D., Ph.D., Paul J. Christos, M.P.H., M.S., Fernando Adriano, R.N., B.S.N., O.C.N., Amy V. Jones, Nicholas C.P. Cross, Ph.D.

Blood (2007) 110 (11): 2530.

https://doi.org/10.1182/blood.V110.11.2530.2530

Published: 2007

Journal Articles

JAK2 Mutations Are Present in All Cases of Polycythemia Vera.

Y. Lynn Wang, M.D., Ph.D., Katherine Vandris, Amy V. Jones, Nicholas C.P. Cross, Ph.D., Paul J. Christos, M.P.H., M.S., Fernando Adriano, R.N., B.S.N., O.C.N., Richard T. Silver, MD

Blood (2007) 110 (11): 4669.

https://doi.org/10.1182/blood.V110.11.4669.4669

Published: 2007

Journal Articles

Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes.

Elizabeth Hyjek, MD, PhD, Amy Chadburn, MD, Nicholas C.P. Cross, PhD, Amy V. Jones, BSc, Su-Chieh P. Sun, MS, Susan Mathew, PhD, April Chiu, MD, April Young, MS, D.M. Knowles, MD, Richard T. Silver, MD

Blood (2006) 108 (11): 4914.

https://doi.org/10.1182/blood.V108.11.4914.4914

Published: 2006

Journal Articles

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

Amy V. Jones, Richard T. Silver, Katherine Waghorn, Claire Curtis, Sebastian Kreil, Katerina Zoi, Andreas Hochhaus, David Oscier, Georgia Metzgeroth, Eva Lengfelder, Andreas Reiter, Andrew J. Chase, Nicholas C. P. Cross

Blood (2006) 107 (8): 3339–3341.

https://doi.org/10.1182/blood-2005-09-3917

Published: 2006

Journal Articles

Validation of JAK2 and New Clinical Criteria for the Diagnosis of Polycythemia Vera (PV).

Richard T. Silver, MD, Amy V. Jones, MD, Eric J. Feldman, MD, Gail J. Roboz, MD, Ellen K. Ritchie, Ph.D, Nicholas C.P. Cross, MD

Blood (2005) 106 (11): 4971.

https://doi.org/10.1182/blood.V106.11.4971.4971

Published: 2005

Journal Articles

No Significant Molecular Response in Polycythemia Vera Patients Treated with Imatinib or Interferon alpha.

Amy V. Jones, BSc, Katherine Higley, BSc, Claire Curtis, BSc, Sebastian Kreil, MD, Katerina Zoi, MSc, Andreas Hochhaus, MD, Andreas Reiter, MD, David Oscier, MD, Alec Merber, BSc, Richard T. Silver, MD, Nicholas C.P. Cross, PhD

Blood (2005) 106 (11): 373.

https://doi.org/10.1182/blood.V106.11.373.373

Published: 2005

Journal Articles

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Blood (2005) 106 (6): 2162–2168.

https://doi.org/10.1182/blood-2005-03-1320

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

EZH2 mutational status predicts poor survival in myelofibrosis

Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms

The JAK2 46/1 haplotype predisposes to MPL -mutated myeloproliferative neoplasms

Decrease in JAK2 V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV).

No Evidence for Increased Prevalence of JAK2 V617F in Women with a History of Recurrent Miscarriage

Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype

JAK2 V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity.

JAK2 Mutations Are Present in All Cases of Polycythemia Vera.

Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes.

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

Validation of JAK2 and New Clinical Criteria for the Diagnosis of Polycythemia Vera (PV).

No Significant Molecular Response in Polycythemia Vera Patients Treated with Imatinib or Interferon alpha.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only